| UHS |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$6.05 vs. cons $5.96 |
MEDIUM |
| UHS |
Report |
Acute same-store revenue growth |
MISS |
pred ~7.0% vs. cons 7.9% |
MEDIUM |
| UHS |
Report |
Behavioral same-store adjusted patient-day growth |
BEAT |
pred ~1.8% vs. cons 1.7% |
LOW |
| UHS |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide $22.64-$24.52 vs. cons $23.52 midpoint |
MEDIUM |
| UHS |
Guide |
FY26 revenue |
UNCHANGED |
guide $18.417B-$18.789B vs. cons $18.551B midpoint |
MEDIUM |
| UHS |
Guide |
FY26 exchange-headwind commentary |
UNCHANGED |
reiterate ~$75M pretax headwind; consensus UNVERIFIED |
LOW |
| UHS |
Return |
Day-1 residual (stock − beta × S&P 500) |
-7.0% |
— |
MEDIUM |
| UHS |
Return |
5-day cumulative residual |
-8.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implicit forward-risk focus |
MEDIUM |